Human primary immunodeficiency diseases are experiments of nature characterized by an increased susceptibility to infection. In many cases, they are also associated with troublesome and sometimes life-threatening autoimmune complications. In the past few years, great strides have been made in understanding the molecular basis of primary immunodeficiencies, and this had led to more focused and successful treatment. This review has 3 aims: (1) to highlight the variety of autoimmune phenomena associated with human primary immunodeficiency diseases; (2) to explore how primary immunodeficiencies predispose patients to autoimmune phenomena triggered by opportunistic infections; and (3) to consider the rationale for the current treatment strategies for autoimmune phenomena, specifically in relation to primary immunodeficiency diseases. Reviewing recent advances in our understanding of the small subgroup of patients with defined causes for their autoimmunity may lead to the development of more effective treatment strategies for idiopathic human autoimmune diseases.

This review is limited largely to immunodeficiency diseases in which the molecular basis of the condition is understood, except in the case of common variable immunodeficiency (CVID) and selective IgA deficiency (SIgAD), which are the most common primary immunodeficiency diseases and which are often associated with autoimmune phenomena. Most primary immunodeficiency diseases have been reviewed recently, and we therefore will not here provide a comprehensive account of all the features of each condition; rather, we will focus on the interrelation among human primary immunodeficiency and autoimmunity. Recent developments in our understanding of the pathogenesis of multigenic autoimmune diseases, including the role of HLA genes and the thymus, were reviewed elsewhere and are not discussed here.1-4 The use of bone marrow transplantation (BMT) in the treatment of severe primary immunodeficiencies, a procedure that may either precipitate or ameliorate autoimmunity, was recently extensively reviewed.5 

For many primary immunodeficiency diseases, the basis of the autoimmunity is the inability of the host to eradicate microbial pathogens and their antigens completely through the usual immune pathways. The result is a compensatory, often exaggerated and chronic inflammatory response by less effective alternative immune pathways, which damage not only infected cells but also surrounding tissue (Figure 1). Thus, in many affected patients, autoimmunity is not a breakdown of tolerance to self-antigens; rather, it is tissue damage incurred as the host attempts to rid itself of foreign immunogens.6 7 

Fig. 1.

Common mechanism of autoimmunity in several primary immunodeficiency diseases.

Fig. 1.

Common mechanism of autoimmunity in several primary immunodeficiency diseases.

Close modal

Classification of autoimmune phenomena in primary immunodeficiency diseases is problematic. One method of classification is based on the underlying genetic defect. This results in a long list that does little to help clinicians plan treatment strategy (Table 1). An alternative classification system is based on the proposed immune pathway causing the autoimmunity (Table 2). This may seem more logical because it indicates the part of the immune system that must be suppressed to control the problem. However, suppression of compensatory immune pathways may not only decrease the inflammation causing the autoimmunity but may also leave the patient open to overwhelming sepsis and death. Furthermore, the problem is likely to recur after the immunosuppression has been reduced because the underlying primary immunodeficiency has not been corrected. A third method of classification—and that used here—is to organize autoimmune phenomena according to which functional component of the immune system is defective (Table 3). This method is based on the idea that treatment should ideally focus on replacing the defective immune component. For many severe primary immunodeficiency diseases, BMT is currently the only effective treatment. Specific gene therapy is still in its infancy.

Table 1.

Genetic defects underlying primary immunodeficiencies associated with autoimmunity

DiseaseGenes
Autoimmune lymphoproliferative syndrome (ALPS) Fas, caspase 10 
Autoimmune polyglandular syndrome I (APECED) Autoimmune regulator  
Hyper-IgM syndrome CD40L, activation-induced cytidine deaminase  
Chediak-Higashi syndrome (CHS) Lysosomal trafficking regulator  
Chronic granulomatous disease (CGD) NADPH oxidase 
Complement deficiencies C1q, C1r, C1s, C2, C4, mannose-binding protein  
Familial hemophagocytic lymphohistiocytosis (FHL) Perforin  
Familial Hibernian fever Type I tumor necrosis factor (TNF) receptor  
Familial Mediterranean fever MEFV 
Griscelli syndrome RAB27A  
Hyper-IgD and periodic fever syndrome Mevalonate kinase  
MHC I deficiency Transporter associated with antigen presentation  
MHC II deficiency CIITA, RFXANF, RFX5, RFXAP  
Leukocyte adhesion deficiency (LAD) CD18 
Omenn syndrome Recombinase-activating genes 1 and 2 
Wiskott-Aldrich syndrome (WAS) Wiskott-Aldrich syndrome protein 
X-linked lymphoproliferative disease (XLP) SLAM-associated protein (SAP) 
DiseaseGenes
Autoimmune lymphoproliferative syndrome (ALPS) Fas, caspase 10 
Autoimmune polyglandular syndrome I (APECED) Autoimmune regulator  
Hyper-IgM syndrome CD40L, activation-induced cytidine deaminase  
Chediak-Higashi syndrome (CHS) Lysosomal trafficking regulator  
Chronic granulomatous disease (CGD) NADPH oxidase 
Complement deficiencies C1q, C1r, C1s, C2, C4, mannose-binding protein  
Familial hemophagocytic lymphohistiocytosis (FHL) Perforin  
Familial Hibernian fever Type I tumor necrosis factor (TNF) receptor  
Familial Mediterranean fever MEFV 
Griscelli syndrome RAB27A  
Hyper-IgD and periodic fever syndrome Mevalonate kinase  
MHC I deficiency Transporter associated with antigen presentation  
MHC II deficiency CIITA, RFXANF, RFX5, RFXAP  
Leukocyte adhesion deficiency (LAD) CD18 
Omenn syndrome Recombinase-activating genes 1 and 2 
Wiskott-Aldrich syndrome (WAS) Wiskott-Aldrich syndrome protein 
X-linked lymphoproliferative disease (XLP) SLAM-associated protein (SAP) 

CD40L indicates CD40 ligand; NADPH, nicotinamide adenine dinucleotide phosphate; MHC, major histocompatibility complex; CIITA, class II transactivator protein; RFX, regulatory factor X; and SLAM, signaling lymphocyte activation molecule.

Table 2.

Proposed mechanisms of autoimmunity in various diseases, autoimmune phenomena, and current treatment options

Proposed mechanism of autoimmunityDiseasesAutoimmune phenomenaTreatment options
Hypersensitivity to persisting viral antigens, especially EBV (T-lymphocyte mediated) CHS, XLP, ? Omenn syndrome Virus-associated HLH Steroids, ATG, MTX, CyA, then BMT  
Steroids, BMT  
 WAS Vasculitis, arthritis Steroids, CyA, BMT  
 ? ALPS Autoimmune cytopenias  
Hypersensitivity to persisting parasitic infection (Cryptosporidium) (T-lymphocyte mediated) CD40L deficiency, MHC II deficiency Sclerosing cholangitis BMT, liver transplantation 
Hypersensitivity response to bacterial antigens, especially gut flora (neutrophil, NK-cell mediated) CGD Granulomatous inflammation of lung, gut, and liver Antibiotics, steroids, interferon-γ, CyA, BMT  
 LAD, BLS-I Leukocytoclastic vasculitis Antibiotics, BMT (for LAD)  
Defective induction of T-cell tolerance in thymus
(T-lymphocyte mediated) 
APECED Organ-specific autoimmunity Alleviation of symptoms  
Defective clearance of antibodies (immune complex mediated) C1q, C1r, C1s, C4 deficiencies SLE Steroids, cyclophosphamide 
Proposed mechanism of autoimmunityDiseasesAutoimmune phenomenaTreatment options
Hypersensitivity to persisting viral antigens, especially EBV (T-lymphocyte mediated) CHS, XLP, ? Omenn syndrome Virus-associated HLH Steroids, ATG, MTX, CyA, then BMT  
Steroids, BMT  
 WAS Vasculitis, arthritis Steroids, CyA, BMT  
 ? ALPS Autoimmune cytopenias  
Hypersensitivity to persisting parasitic infection (Cryptosporidium) (T-lymphocyte mediated) CD40L deficiency, MHC II deficiency Sclerosing cholangitis BMT, liver transplantation 
Hypersensitivity response to bacterial antigens, especially gut flora (neutrophil, NK-cell mediated) CGD Granulomatous inflammation of lung, gut, and liver Antibiotics, steroids, interferon-γ, CyA, BMT  
 LAD, BLS-I Leukocytoclastic vasculitis Antibiotics, BMT (for LAD)  
Defective induction of T-cell tolerance in thymus
(T-lymphocyte mediated) 
APECED Organ-specific autoimmunity Alleviation of symptoms  
Defective clearance of antibodies (immune complex mediated) C1q, C1r, C1s, C4 deficiencies SLE Steroids, cyclophosphamide 

EBV indicates Epstein-Barr virus; HLH, hemophagocytic lymphohistiocytosis; ATG, antithymocyte globulin; MTX, methotrexate; CyA, cyclosporine; BMT, bone marrow transplantation; NK, natural killer; BLS-I, bare lymphocyte syndrome type I; and SLE, systemic lupus erythematosus. For explanation of other abbreviations, see Table1.

Table 3.

Primary immunodeficiency diseases associated with autoimmunity

Main defect in immunityImmunodeficiency diseasesAutoimmune phenomena
Neutrophil defects CGD Fibrosing granulomatous inflammation in lung, liver, and gut; SLE 
 LAD Leukocytoclastic vasculitis  
Complement defects Complement deficiencies SLE  
B-cell defects XLA None  
NK-cell defects CHS, Griscelli syndrome, XLP, FHL Virus-associated HLH  
T-cell, T-cell–associated defects Omenn syndrome Graft-versus-host–like disease 
 APECED Organ-specific autoimmune disease (parathyroid, adrenal, gonads pancreas, skin, etc)  
 ALPS Autoimmune cytopenias (anemia, thrombocytopenia, neutropenia)  
 CD40L deficiency Sclerosing cholangitis  
 MHC II deficiency Sclerosing cholangitis, autoimmune cytopenias 
 WAS Anemia, vasculitis, arthritis, nephritis 
 CVID Granulomatous disease, autoimmune cytopenias, arthritis, inflammatory bowel disease  
Cytokine overactivity Familial Mediterranean fever Polyserositis, arthritis, HSP, PAN  
 Hyper-IgD syndrome with periodic fever  
 TNF-receptor–associated periodic fever (familial Hibernian fever)  
Main defect in immunityImmunodeficiency diseasesAutoimmune phenomena
Neutrophil defects CGD Fibrosing granulomatous inflammation in lung, liver, and gut; SLE 
 LAD Leukocytoclastic vasculitis  
Complement defects Complement deficiencies SLE  
B-cell defects XLA None  
NK-cell defects CHS, Griscelli syndrome, XLP, FHL Virus-associated HLH  
T-cell, T-cell–associated defects Omenn syndrome Graft-versus-host–like disease 
 APECED Organ-specific autoimmune disease (parathyroid, adrenal, gonads pancreas, skin, etc)  
 ALPS Autoimmune cytopenias (anemia, thrombocytopenia, neutropenia)  
 CD40L deficiency Sclerosing cholangitis  
 MHC II deficiency Sclerosing cholangitis, autoimmune cytopenias 
 WAS Anemia, vasculitis, arthritis, nephritis 
 CVID Granulomatous disease, autoimmune cytopenias, arthritis, inflammatory bowel disease  
Cytokine overactivity Familial Mediterranean fever Polyserositis, arthritis, HSP, PAN  
 Hyper-IgD syndrome with periodic fever  
 TNF-receptor–associated periodic fever (familial Hibernian fever)  

XLA indicates X-linked agammaglobulinemia; CVID, common variable immunodeficiency; HSP, Henoch-Schönlein purpura; and PAN, polyarteritis nodosa. For explanation of other abbreviations, see Tables 1 and 2.

Phagocyte disorders

Chronic granulomatous disease.

Chronic granulomatous disease (CGD) consists of a group of X-linked and autosomal recessive disorders of neutrophil production of nicotinamide adenine dinucleotide phosphate oxidase that affect 1 in 200 000 children. In these disorders, neutrophils are incapable of completely eradicating phagocytosed catalase-positive bacteria and fungi. Patients have recurrent bacterial and fungal (especially Aspergillus) infections that may affect any part of the body, including the skin, lungs, liver, and bone. Death is usually caused by respiratory failure. The average patient survives to the age of 20 years.8 9 

Along with infective complications, chronic inflammation of the gut (similar to Crohn disease) is a common (occurring in 50% of patients) although less well-recognized cause of morbidity in patients with CGD. Gastrointestinal symptoms of abdominal pain, diarrhea, and malabsorption respond variably to immunomodulatory agents (prednisolone, cyclosporin A, and interferon-γ), and there is an increased risk of reactivating latent infection.10-12Inflammation can occur anywhere from mouth to anus. Widespread granuloma formation and fibrosis may result in stomatitis and oral ulcers; esophagitis associated with dysphagia, dysmotility, and obstruction; gastric outlet obstruction and eosinophilic gastritis; intestinal villous atrophy or granulomatous colitis; and liver fibrosis and cirrhosis. Chronic inflammation in other systems, such as the lungs, may produce fibrosis and cor pulmonale. Specific pathogens are usually not isolated. The pathogenesis of this chronic inflammation is unknown, but one possibility is that the inability to eradicate bacterial and fungal immunogens completely promotes a chronic inflammatory reaction that destroys surrounding tissue.13Carriers of the defective genes involved may not be entirely asymptomatic: 10% of X-linked recessive kindred and 3% of autosomal recessive kindred have family members with discoid lupus.9 

Because of the poor long-term prognosis in CGD, early BMT is now being recommended by many specialist centers if a matched sibling donor is available.14 Although gene therapy for CGD has been attempted, it has not been successful.

Leukocyte adhesion molecule deficiency.

Leukocyte adhesion molecule deficiency (LAD) is due to defects in integrin family adhesion molecules (CD18) that are essential for binding of neutrophils to the endothelial surface as a prerequisite to infiltration into inflamed tissues. Consequently, patients with LAD have high circulating neutrophil counts, resulting in severe, recurrent life-threatening infections associated with a lack of pus formation.15 Persistence of bacterial antigens and the inability of neutrophils to escape from the circulation may produce a persistent leukocytoclastic vasculitis. Early death can be averted only by BMT.

Major histocompatibility complex class I deficiency (bare lymphocyte syndrome type I)

Major histocompatibility complex class I (MHC I) deficiency is rare and has a variable clinical phenotype that ranges from totally asymptomatic to a condition similar to that resulting from severe combined immunodeficiency (SCID).16 Mutations in the genes coding for the transporter associated with antigen presentation (TAP) have been found in patients with this disorder. TAP mediates the translocation of foreign peptide from the proteasome into the endoplasmic reticulum so that it can combine with HLA-I molecules, an essential step in the presentation of MHC I–peptide complexes on the cell surface. Patients deficient in TAP have reduced cell-surface expression of MHC I. Immunity to viruses appears intact, with normal antibody titers, but chronic recurrent bacterial sinopulmonary infections are a major problem and patients have a course similar to those of patients with cystic fibrosis and ciliary dyskinesia. Chronic pulmonary infection may cause a reactive cutaneous leukocytoclastic vasculitis and a polyarthritis.16 Necrotizing granulomatous inflammation of the nose and skin may resemble manifestations of Wegener granulomatosis or lethal midline granuloma.17 Histologic assessment of the granuloma shows large numbers of activated natural killer (NK) cells. Unlike patients with Wegener granulomatosis, patients with MHC I deficiency do not have glomerulonephritis or proteinase 3–antineutrophil cytoplasmic antibodies. Immunosuppressive therapy using steroids and cyclophosphamide worsens the clinical condition because it dampens the host immune response to the chronic infection. Care of these patients should include regular chest physiotherapy and antibiotic therapy.

Antibody production appears to be intact in MHC I deficiency, since patients have normal viral titers and a polyclonal hypergammaglobulinemia. Cellular immunity also appears to be unaffected: NK-cell–mediated and T-cell–mediated immunity to viruses is normal and skin testing using purified tuberculin may yield positive results. Thus, it is not known why patients with this disorder are susceptible to pyogenic bacterial infections.

NK-cell disorders

Chediak-Higashi syndrome and Griscelli syndrome.

These syndromes are autosomal recessive diseases characterized by partial oculocutaneous albinism, a mild predisposition to pyogenic infections, and in Chediak-Higashi syndrome (CHS), abnormally large granules in many different cell types.18 Griscelli syndrome is differentiated from CHS by the presence of pathognomonic light and electron microscopical features in skin and hair and the absence of consistent granulocyte abnormalities. Mutations in the large lysosomal trafficking regulator gene that lead to truncation of the protein cause CHS.19,20 Mutations in the guanosine triphosphate (GTP)–binding protein RAB27A, which is involved in cytotoxicity and cytolytic granule exocytosis pathways, occur in Griscelli syndrome.21 

Susceptibility to infection in patients with these syndromes may be due to defects in NK- and T-cell–mediated cytotoxicity, especially to herpes viruses, as well as defects in chemotaxis and the bactericidal capacity of granulocytes and monocytes. The accelerated phase of the disease, which is characterized by virus-induced hemophagocytic lymphohistiocytosis (HLH), has never been observed in animal models, possibly because the Epstein-Barr virus (EBV) is specific to humans.22 Many children with CHS or Griscelli syndrome will die young, largely as a result of EBV-triggered HLH, unless treated with BMT.

Familial hemophagocytic lymphohistiocytosis.

Familial hemophagocytic lymphohistiocytosis (FHL) is a rare, rapidly fatal autosomal recessive immune disorder characterized by uncontrolled activation of T cells and macrophages and overproduction of inflammatory cytokines. The disease is due to a defect in the perforin gene.23 Perforins are a class of proteins present in the secretory granules of NK and T lymphocytes that mediate cytotoxicity by polymerizing to form pores in target-cell membranes in a way similar to that of a structurally related protein, complement factor C9. Although FHL is considered a NK-cell disorder, its pathogenesis involves dysfunction of T cells. Incomplete clearance of triggering viruses results in a persistent, exaggerated inflammatory response with tissue destruction. After control of the HLH with immunosuppressive drugs, the treatment of choice is BMT.24 25 

X-linked lymphoproliferative disease.

X-linked lymphoproliferative disease (XLP), previously called Duncan disease,26 is due to a defect in SLAM-associated protein.27 28 The disease is characterized by an inability to mount an effective immune response to EBV. EBV-driven B-cell lymphoproliferative disease develops in 30% of patients and is usually fatal.

Alternatively, persistent infection may be associated with an ineffectual but damaging T-cell–mediated inflammatory response. If generalized, the result is virus-associated HLH (58%); if more localized to the infected lymphocytes, aplastic anemia (3% of patients) or isolated hypogammaglobulinemia (31%) may develop.29 Three percent of boys have an exaggerated T-lymphocyte response to EBV-infected B cells lodging in lung tissue and vessel walls, resulting in pulmonary lymphomatoid granulomatosis associated with a lymphoid vasculitis.30,31A similar T-cell reaction has been observed in boys with Wiskott-Aldrich syndrome (WAS).32 Aggressive combination chemotherapy with or without radiotherapy33 and interferon-α2b therapy34 have produced encouraging improvements in survival of patients with lymphomatoid granulomatosis. Anti–B-cell monoclonal antibodies that destroy B cells—some of which are infected with EBV—have also been used with some success to treat this condition.35 

The immune mechanisms underlying the clinical features of XLP are becoming clearer. Defective NK-cell and cytotoxic T-lymphocyte activity due to aberrant activity of the cytoplasmic lymphocyte activation proteins 2B4 and SLAM result in persistence of the EBV virus that leads to serious clinical disease.36-38 Reduced NK-cell activity has been found in other patients with unusually severe or prolonged EBV infections.39-42 Augmented activation of NK cells by recombinant interleukin 2 has been used successfully to treat patients with chronic EBV infection,43 although it has not so far been used in XLP.

The prognosis for XLP is extremely poor, with 70% of boys dying before the age of 10 years.29 As with many other rare immunodeficiencies, BMT before tissue damage occurs is recommended. Children who present with virus-associated HLH have been treated successfully with HLH chemotherapy protocols.44 

Complement deficiencies

Deficiencies in components of complement are rare, with the most common being a deficiency in C2 that occurs in 1 in 20 000 people. Only deficiencies in the earlier components of the classical pathway (C1q, C1r, C1s, C2, and C4) have been linked to autoimmune diseases.45,46 One percent of patients with systemic lupus erythematous (SLE) have defects in their complement pathway. C1q deficiency occurred with SLE in 38 of 41 cases (92%) reported. Among such patients, SLE tends to be more severe, the age of onset is earlier (median age, 7 years), and a preponderance of male patients is observed. Patients with deficiencies in C1r and C1s that often occur together and C4 deficiencies have a similar propensity to SLE (60%-75%). Homozygous C2 deficiency is associated with SLE, SLE-like disease, or immune complex disease in 50% of cases. Heterozygous complement deficiencies do not produce an increased prevalence of autoimmunity. A deficiency of mannose-binding protein, which cleaves C4 and C2 when bound to antibody in the same way as activated C1s, has been linked to an increase in autoimmune disorders (arthritis, idiopathic thrombocytopenic purpura [ITP], enteropathy, pernicious anemia, and vitiligo) when associated with CVID.47 The exact mechanism by which complement deficiencies cause autoimmunity is unknown. The fact that it is C1q that binds to the Fc component of IgG or IgM and apoptotic cells suggests that the lack of interaction of complement with immunoglobulin and these cells may prevent the cells' clearance, thereby leading to production and buildup of circulating autoantibodies.48 49 

T-cell disorders

Omenn syndrome.

Omenn syndrome is a form of SCID associated with ineffectual T-lymphocyte responses to all infections. Patients have overwhelming viral, bacterial, fungal, or parasitic infections leading to death in infancy. The disorder is caused by mutations in recombination-activating genes (RAG) 1 and 2 that result in a partial absence of the protein product.50,51 RAG is involved in immunoglobulin and T-cell–receptor gene recombination and thus the generation of immune diversity. Defective development of lymphocytes causes a systemic autoimmune reaction (with lymphadenopathy, splenomegaly, erythroderma, autoimmune hepatic dysfunction and failure, and encephalopathy) that is similar to HLH and that characterizes Omenn syndrome.52 53 Children with Omenn syndrome will die unless treated with BMT. Dysfunctional T-lymphocyte activity is controlled by administering a combination of high-dose steroids, antithymocyte globulin, and cyclosporin A (HLH protocol) before transplantation.

Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (autoimmune polyglandular syndrome type 1).

Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a rare autoimmune disease that primarily affects the endocrine glands.54 The typical triad for APECED is hypoparathyroidism (85% of patients), primary adrenocortical failure (72%), and chronic mucocutaneous candidiasis (100%). Gonadal failure (60%), diabetes mellitus (18%), and pernicious anemia (13%) may also occur. Ectodermal manifestations include dystrophy of the dental enamel (77%) and nails (52%). The most life-threatening complications are oral squamous cell carcinoma and fulminant autoimmune hepatitis. The disease prevalence is especially high in Finland, among Iranian Jews, and in the Sardinian population.

Mutations in the autoimmune regulator (AIRE) gene cause this organ-specific human autoimmune disease.55 It was suggested that through transcriptional regulation, AIRE is involved in the negative selection or anergy induction of self-reactive lymphocytes in the thymus.56-59 

Patients with chronic mucocutaneous candidiasis (CMC) have similar problems with Candida infections and autoimmune polyendocrinopathies but no ectodermal dysplasia. The underlying gene defect in CMC is unknown.60 

Autoimmune lymphoproliferative syndrome.

Patients with type I Autoimmune lymphoproliferative syndrome (ALPS; Canale-Smith syndrome) have a defect in Fas, a member of the tumor necrosis factor (TNF) superfamily.61,62 A mutation in caspase 10, another cellular component of the same apoptotic pathway, has been found in patients with type II ALPS.63 ALPS does not produce an overt increase in propensity to infections. The principal clinical features are chronic benign lymphoproliferation (lymphadenopathy and splenomegaly) and autoimmune disease (especially autoimmune cytopenias, although other organ-specific autoimmune phenomena also occur).62,64 The precise trigger for the clinical features of the disease is still unknown, but common childhood herpes virus infections (human herpesvirus 6, cytomegalovirus, and EBV infections) that induce a lymphoproliferative response though cleared normally may be involved.65 

The prognosis for children with Fas deficiency is generally good unless they have the very rare homozygous form of the disease, for which early BMT is recommended. The heterozygous form tends to improve spontaneously with age and without treatment. Patients and their families appear to have an increased risk of both Hodgkin (51-fold increase) and non-Hodgkin (14-fold increase) lymphomas.66 

CD40 ligand deficiency (hyper-IgM syndrome).

CD40 ligand (CD40L), like Fas, is a member of the TNF superfamily, involved in T-cell–mediated cytolysis and T-cell–dependent, B-cell antibody responses. It is the gene underlying the X-linked form of hyper-IgM syndrome.67 Defects in the activation-inducing cytidine deaminase gene cause an autosomal recessive form of the disorder.68 Hyper-IgM syndrome was initially characterized as a humoral immunodeficiency with a delay in the class switching from IgM production (normal or high levels of serum IgM) to immunoglobulin molecules of other classes (low IgG, IgA, and IgE levels) associated with sinopulmonary infections.69 Pneumocystis carinii pneumonia (PCP) is common in patients with hyper-IgM syndrome but is not characteristic of humoral immunodeficiencies. The increased prevalence of PCP is not related to the humoral immune abnormalities but is due to the inability of T lymphocytes to induce apoptosis of pulmonary epithelium infected with Pneumocystisorganisms.70 

A principal cause of death in patients with hyper-IgM syndrome who reach adolescence or young adulthood is liver failure due to sclerosing cholangitis.71,72 The mechanism for this organ-specific autoimmune phenomenon has been described. Cryptosporidiumgastroenteritis is common in these patients, and Cryptosporidiumparasites may also ascend the biliary tree and infect bile duct epithelium. The inability of T lymphocytes to induce destruction of infected cells results in persistence of the pathogen, chronic inflammation, and subsequently, sclerosing cholangitis.73In contrast to the increase in destructive cellular immune responses, patients with CD40L deficiency have a reduction in self-reactive antibodies, a finding that illustrates the essential role of functional interactions between CD40 and CD40L in the selection of natural self-reactive B-cell repertoires.74 

The long-term prognosis for patients with hyper-IgM syndrome is poor; 50% of boys with the disorder are dead by the age of 20 years. Definitive treatment with BMT in early childhood is recommended.75 Children who undergo BMT after liver damage occurs have a significantly poorer outcome post-BMT, largely because of graft-versus-host disease in the diseased liver that results in liver failure and often death if liver transplantation is not done.76 77 

MHC class II deficiency.

MHC II deficiency consists of a group of rare autosomal recessive conditions caused by mutations in 4 genetic complementation groups or regulatory proteins involved in MHC II gene expression.78All cells derived from bone marrow, as well as thymic epithelium critical for the maturation of CD4+ T cells, have no MHC class II expression and a resultant CD4+ T lymphopenia. Patients with MHC class II deficiency usually die in infancy of overwhelming infections, especially disseminated viral infections.79-81 BMT is the only curative therapy, although success rates are lower than for SCID and the CD4+T lymphopenia persists.82 As with CD40L deficiency, incomplete clearance of parasites can lead toCryptosporidium-associated sclerosing cholangitis (up to 16% of cases). Autoimmune cytopenias also occur in up to 19% of patients.83 

Wiskott-Aldrich syndrome.

WAS is a rare X-linked immunodeficiency disorder caused by a maturational defect affecting both lymphocytes and platelets. Death in childhood (mean age, 11 years) is due to hemorrhage (23% of patients), infection (44%), or EBV-driven lymphomas (26%).84 Eczema is common (81%); autoimmune problems occur in children with the more severe phenotype (40%) and are associated with an increased risk of EBV-related lymphoid cancer (P < .001). In a review, Sullivan et al85 observed that 15 of 20 nonperitransplantation cases of malignant disease (75%) occurred in patients with a history of autoimmune disease. Conversely, malignant disease ultimately developed in 25% of patients with a history of autoimmune disease but in just 5% of patients without such a history. These data suggest that EBV, which underlies malignant disease in patients with WAS, may also trigger the autoimmunity. The most common autoimmune problems are hemolytic anemia and vasculitis, followed by renal disease and arthritis. In some boys, clinical features similar to those in Kawasaki disease are observed.86 SLE, Sjögren syndrome, autoimmune endocrinopathies, and sarcoidosis do not occur.85 

The gene responsible for WAS (WAS protein) is expressed in all hematopoietic stem cell–derived lineages and may play a role in the regulation of the actin-cytoskeleton system by interacting directly with the Ρ-like GTPase cdc42.87 88 The immune problems in WAS are not static, and there is a continual deterioration in immune function.

Symptomatic treatment with intravenous immunoglobulin, splenectomy, steroids, and antibiotic prophylaxis should be used only as a holding measure.85,89 It is clear that BMT is the treatment of choice and should be done before patients reach school age and have cumulative tissue damage due to infection and autoimmune disease.86 

Common variable immunodeficiency.

CVID is the most common symptomatic primary antibody deficiency syndrome. It is characterized clinically by recurrent sinopulmonary and gastrointestinal infections. Chronic bronchiectasis leading to respiratory failure is a common cause of premature death. Many patients require immunoglobulin-replacement therapy, prophylactic antibiotic treatment, or both.

CVID is not a single disease but an idiopathic group of diseases characterized by various degrees of defective antibody production, ranging from isolated defects in the production of antibody to carbohydrate antigens to almost complete absence of all immunoglobulin subclasses.90 Leaky phenotypes of SCIDs and the molecular defects listed in Table 4 are sometimes found in patients presenting with clinical features suggestive of CVID. A greater understanding of the molecular genetic background of primary immunodeficiency disorders will lead to a smaller proportion of patients being considered to have CVID and a larger proportion given a diagnosis of a defined primary immunodeficiency disease. This will allow more accurate advice to be given on the possible complications and likely natural history of a patient's condition.

Table 4.

Molecular defects found in some patients considered to have CVID

Defect typeResult
Underlying B-cell defects  
 Defective B-cell cytoplasmic second messengers (Btk)121 X-linked agammaglobulinemia  
 Deletions in immunoglobulin genes122  
Underlying T-cell defects  
 Defective T-cell surface receptors (CD40L)123 CD40L deficiency  
 Defective T-cell cytoplastic second messengers (lck, SAP)124 125  X-linked lymphoproliferative disease, SCID (forme fruste)  
 Defective cell cycling, DNA repair enzymes126 Ataxia-telangiectasia, Nijmegen breakage syndrome  
 Defective purine salvage pathway metabolism127 ADA, PNP deficiency 
Defect typeResult
Underlying B-cell defects  
 Defective B-cell cytoplasmic second messengers (Btk)121 X-linked agammaglobulinemia  
 Deletions in immunoglobulin genes122  
Underlying T-cell defects  
 Defective T-cell surface receptors (CD40L)123 CD40L deficiency  
 Defective T-cell cytoplastic second messengers (lck, SAP)124 125  X-linked lymphoproliferative disease, SCID (forme fruste)  
 Defective cell cycling, DNA repair enzymes126 Ataxia-telangiectasia, Nijmegen breakage syndrome  
 Defective purine salvage pathway metabolism127 ADA, PNP deficiency 

SCID indicates severe combined immunodeficiency; ADA, adenosine deaminase; and PNP, purine nucleoside phosphorylase. For explanation of other abbreviations, see Tables 1 and 3.

Although the hallmark of CVID is defective antibody production, in many cases, B-cell dysfunction is due to a lack of help from defective T lymphocytes, since in vitro tests of isolated B-cell function yield normal results in 75% of cases. More than half of patients with CVID have abnormal T-cell numbers or defective proliferation to mitogens.

Autoimmune diseases, particularly chronic inflammatory bowel disease, autoimmune cytopenias such as thrombocytopenia and hemolytic anemia, and rheumatoid arthritis, are common in patients with CVID.91,92 Inflammatory bowel disease associated with chronic diarrhea and sometimes malabsorption, failure to thrive, or protein-losing enteropathy, occurs in about 30% of patients and most often affects the large bowel, although it can affect the stomach or small bowel.93,94 If the stomach is involved, associated atrophic gastritis and pernicious anemia may occur. The inflammatory bowel disease may have histologic features of celiac disease, Crohn disease, or acute graft-versus host disease, with villous atrophy, apoptotic bodies in crypts, and lymphocyte infiltration. In up 16% of patients with CVID, cancer develops, particularly gastric adenocarcinoma and small-bowel lymphoma that arise in the presence of severe atrophic gastritis and nodular lymphoid hyperplasia, respectively.95 96 

Liver disease with persistently elevated levels of liver enzymes develops in 20% of patients with CVID. In some cases, liver disease is due to viral hepatitis, although with screening of immunoglobulin-replacement agents for hepatitis viruses, this should now be rare. In other cases, the cause is unknown. Granuloma or mild inflammatory changes in the portal tracts are often found at liver biopsy.97 

Autoimmune disease in patients with CVID may be associated with particular HLA and mannose-binding protein genotypes.98Steroids and other immunosuppressive agents frequently used to treat autoimmune diseases should be used with caution in patients with CVID because such drugs will further increase the patients' risk of infection.

About 10% of patients with CVID have multisystem, noncaseating granulomatous disease. CVID-associated granulomatous disease can affect solid organs, skin, gut, lymph nodes, and spleen, and it may be confused with idiopathic sarcoidosis,99,100 CGD, or Crohn disease. Patients with granulomatous disease often have clinical evidence of lymphoproliferation (splenomegaly and lymphadenopathy),101 and laboratory testing frequently shows an expansion of CD8+ T lymphocytes that may underlie the inflammatory reaction.102 The lungs (interstitial lung disease) and gut (chronic inflammatory disease) are the principal sites affected. Specific HLA types may be associated with granulomatous disease in CVID. Functional polymorphisms in the TNF gene in the HLA class III region related to increased TNF production are associated with granuloma in patients with CVID.98 

Isolated IgA deficiency or SIgAD.

SIgAD is the most common form of primary immunodeficiency disease in the Western world (1 in 600), although it is less common in the Japanese (1 in 18 000) and Chinese (1 in 4000) populations.103 Familial inheritance of either SIgAD or CVID occurs in about 20% of cases, and CVID may develop from SIgAD, suggesting that at least in some cases, SIgAD and CVID may be part of a spectrum of diseases caused by common, not-yet-identified genetic factors.94 Most people with SIgAD are asymptomatic and do not have an increased risk of infection. Patients with recurrent infections, particularly respiratory and gastrointestinal infections, often have other antibody defects and are therefore more appropriately classified as having CVID.

Patients with SIgAD have an increased risk of autoimmune phenomena, especially systemic autoimmune diseases such as SLE (1%-5% of patients) and rheumatoid arthritis (2%-4% of patients).104 There is also a clear link between SIgAD and celiac disease. The prevalence of SIgAD in patients with celiac disease is 2.6%, which represents a 10- to 16-fold increase over that in the general population.105 An increased risk of other organ-specific autoimmune diseases, such as insulin-dependent diabetes mellitus, myasthenia gravis, and autoimmune thyroiditis, has been reported, but the evidence for such associations is insufficient, and larger studies are required before definite conclusions can be drawn.

A high prevalence of autoantibodies (especially rheumatoid factor, anticardiolipin, and antinuclear antibodies) not associated with any clinical disease occurs in patients with SIgAD.104Antibodies against ingested food antigens are also common. Anti-IgA antibodies, especially those of the IgG subclass, are found in 9% to 44% of patients with complete, but not partial, SIgAD. Although reactions to blood products in patients with SIgAD are uncommon (1 in 30),106 anti-IgA antibodies increase the risk of severe or even fatal reactions to blood, plasma, and agents used in immunoglobulin-replacement therapy.107 There is no correlation between the titer of anti-IgA antibodies of the IgG and IgM class and the severity of transfusion reactions. The risk of anaphylaxis may be related to the production of antibodies of the IgE isotype.108 Blood products should be administered with caution to patients with SIgAD, and intravenous immunoglobulin products with low levels of IgA (< 1 mg/L) are often recommended.109 

There are several theories for why patients with SIgAD have an increased risk of autoimmunity. IgA on mucosal surfaces may bind to environmental antigens, promoting their removal and preventing development of secondary T-cell–mediated inflammatory responses. Certain HLA alleles and haplotypes (eg, HLA-A1, HLA-B8, and HLA-DR3) associated with autoimmune diseases are also associated with SIgAD.110 Production of IgA is known to be strictly T-cell dependent, and some patients with SIgAD have CVID and overt abnormalities in T-cell regulation. T-cell dysfunction may be responsible for both SIgAD and the autoimmunity.104 

DiGeorge syndrome.

A few anecdotal reports have described immune cytopenias and ITP in children with 22q11 deletions (DiGeorge syndrome).111 112Additional studies are required to determine the extent to which autoimmune diseases occur in patients with this T-cell immunodeficiency.

Cytokine storms

Hereditary febrile disorders.

Some rare disorders are characterized by recurrent episodes of fever and autoimmune phenomena. Familial Mediterranean fever (FMF) is an autosomal recessive disorder that chiefly affects people from the Mediterranean basin and is caused by mutations in the pyrin-marenostrin (MEFV) gene.113 MEFV, a member of a highly conserved group of nuclear transcription factor genes, is expressed in neutrophils, eosinophils, and monocytes114 and is thought to provide inhibitory signals that may decrease inflammatory responses by these cells.115 FMF is characterized clinically by recurrent episodes of fever, polyserositis, and arthritis, which occurs in almost half of the patients and is usually monoarticular. Up to 47% of patients have Henoch-Schönlein purpura with a leukocytoclastic vasculitis, and 9% have polyarteritis nodosa.116-118 In one series, 12 of 16 patients had high levels of antistreptolysin O titer, suggesting a possible role for streptococcal infections in triggering the vasculitis.117 Amyloidosis develops in 25% of patients. Colchicine is the treatment of choice for both prophylaxis and acute exacerbations of FMF.

TNF-receptor (TNFR)–associated periodic syndrome (TRAPS) is an autosomal dominant condition caused by missense mutations in the gene encoding type I TNFR.119 The mutations may produce an inability to cleave the extracellular domain of the TNFR, thereby leading to a persistent, exaggerated response to TNF. Patients with TRAPS may have fever, polyserositis, arthritis, rash, and conjunctivitis; amyloidosis occurs in 25%. Clinical improvement in TRAPS has been observed after infusions of p75 TNFR–Fc fusion proteins.118 

Hyperimmunoglobulinemia D and periodic fever syndrome, in which patients have fever, polyserositis, arthritis, lymphadenopathy, and cutaneous vasculitis, is due to mutations in the gene encoding mevalonate kinase.120 Mevalonic kinase catalyzes conversion of mevalonic acid to 5-phosphomevalonic acid during biosynthesis of cholesterol and nonsterol isoprene compounds, but the mechanism by which mutations in the gene cause inflammation is unknown. Nonsteroidal anti-inflammatory agents may partly control symptoms.

It is currently assumed that autoimmunity is a breakdown in self-tolerance. However, advances in our understanding suggest that autoimmunity associated with primary immunodeficiency diseases is not simply defective self-tolerance; rather, it is the inability of an inherently defective immune system to eradicate persisting microbial immunogens. Persistence of an antigen results in chronic, ineffective, damaging immune responses (Table 2). Herpes viruses are the archetypal persisting infectious agents that, even in individuals with essentially normal immunity, intermittently escape from normal immune control and produce symptomatic disease. It is therefore not surprising that incomplete eradication or relapse of EBV seems to trigger autoimmune phenomena. Examples include virus-associated HLH in CHS, Griscelli syndrome, FHL, and XLP; lymphomatoid vasculitis in XLP and lymphomatoid vasculitis; and possibly other vasculitides in WAS. Most animals are resistant to EBV, and the classic virus-associated HLH of the NK-cell disorders does not occur, limiting the usefulness of animals as models for these diseases. Boys with X-linked agammaglobulinemia have no B lymphocytes and therefore cannot be chronically infected with EBV. Autoimmunity is not a feature of this B-cell disorder.

This review highlighted the great variety of genetic defects that may predispose an individual to autoimmunity (Table 1). Mutated genes are involved in a variety of cellular functions. In some cases, it is difficult to reconcile the underlying genetic defect (eg, MEFV and mevalonate kinase) with the clinical disease, and therefore candidate-gene screening approaches may not always be useful. The fact that mutations in a variety of genes may result in almost identical clinical phenotypes (eg, HLH in XLP and FHL and ALPS in Fas and caspase-10 deficiency) is likely to complicate population studies aimed at determining genetic predisposition for specific autoimmune syndromes. Studies in animals will help explain why a particular autoimmune disease develops in a particular inbred strain, but results should be applied cautiously to human disease.

Despite these difficulties, studies of autoimmunity in primary immunodeficiency diseases and of their underlying molecular defects have allowed clinicians to predict the natural history of these conditions and to optimize clinical management. In our pediatric immunology practice, we have created strong collaborative links with clinical colleagues in other specialties, including rheumatology, gastroenterology, and particularly hematology, as well as with scientists in laboratories around the world. This has led to a diagnosis in several patients and their relatives, some of whom were thought to have had an “idiopathic” autoimmune disease for many years. Strengthening of links and communication among clinicians in a variety of specialties and development of collaborative research with basic scientists has and will continue to provide the best means for translating the advances in understanding autoimmunity in primary immunodeficiency diseases to idiopathic autoimmunity.

1
Davidson
A
Diamond
B
Autoimmune diseases.
N Engl J Med.
345
2001
340
350
2
Marrack
P
Kappler
J
Kotzin
BL
Autoimmune disease: why and where it occurs.
Nat Med.
7
2001
899
905
3
Sonderstrup
G
McDevitt
HO
DR, DQ and you: MHC alleles and autoimmunity.
J Clin Invest.
107
2001
795
796
4
Theofilopoulos
AN
Dummer
W
Kono
DH
T cell homeostasis and systemic autoimmunity.
J Clin Invest.
108
2001
335
340
5
Sherer
Y
Shoenfeld
Y
Autoimmune diseases and autoimmunity post-bone marrow transplantation.
Bone Marrow Transplant.
22
1998
873
881
6
Fairweather
D
Kaya
Z
Shellam
GR
Lawson
CM
Rose
NR
From infection to Autoimmunity.
J Autoimmun.
16
2001
175
186
7
Panoutsakopoulou
V
Cantor
H
On the relationship between viral infection and autoimmunity.
J Autoimmun.
16
2001
341
345
8
Finn
A
Hadzic
N
Morgan
G
Strobel
S
Levinsky
RJ
Prognosis of chronic granulomatous disease.
Arch Dis Child.
65
1990
942
945
9
Winkelstein
JA
Marino
MC
Johnston
RB
Jr
et al
Chronic granulomatous disease. Report on a national registry of 368 patients.
Medicine (Baltimore).
79
2000
155
169
10
Ament
ME
Ochs
HD
Gastrointestinal manifestations of chronic granulomatous disease.
N Engl J Med.
288
1973
382
387
11
Barton
LL
Moussa
SL
Villar
RG
Hulett
RL
Gastrointestinal complications of chronic granulomatous disease: case report and literature review.
Clin Pediatr.
37
1998
231
236
12
Rosh
JR
Tang
HB
Mayer
L
Groisman
G
Abraham
SK
Prince
A
Treatment of intractable gastrointestinal manifestations of chronic granulomatous disease with cyclosporine.
J Pediatr.
126
1995
143
145
13
Bratt
J
Palmblad
J
Cytokine-induced neutrophil-mediated injury of human endothelial cells.
J Immunol.
159
1997
912
918
14
Ozsahin
H
von Planta
M
Mueller
I
et al
Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilizing granulocytes, and liposomal amphotericin-B.
Blood.
92
1998
2719
2724
15
Etzioni
A
Adhesion molecules—their role in health and disease.
Pediatr Res.
39
1996
191
198
16
Gadola
SD
Moins-Teisserenc
HT
Trowsdale
J
Gross
WL
Cerundolo
V
TAP deficiency syndrome.
Clin Exp Immunol.
121
2000
173
178
17
Moins-Teisserenc
HT
Gadola
SD
Cella
M
et al
Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules.
Lancet.
354
1999
1598
1603
18
Sato
A
Chediak-Higashi disease: probable identity of a “new leukocyte anomaly (Chediak)” and “congenital gigantism of peroxidase granules (Higashi).”
Tohoya J Exp Med.
61
1955
201
19
Barbosa
MD
Nguyen
QA
Tchernev
VT
et al
Identification of the homologous beige and Chediak-Higashi syndrome genes.
Nature.
382
1996
262
265
20
Nagle
DL
Karim
MA
Woolf
EA
et al
Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome.
Nat Genet.
14
1996
307
311
21
Menasche
G
Pastural
E
Feldmann
J
et al
Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome.
Nat Genet.
25
2000
173
176
22
Windhorst
DB
Padgett
G
The Chediak-Higashi syndrome and the homologous trait in animals.
J Invest Dermatol.
60
1973
529
537
23
Stepp
SE
Dufourcq-Lagelouse
R
Le Deist
F
et al
Perforin gene defects in familial hemophagocytic lymphohistiocytosis.
Science.
286
1999
1957
1959
24
Collins
P
Watts
M
Brocklesby
M
Gerritsen
B
Veys
P
Successful engraftment of haploidentical stem cell transplant for familial haemophagocytic lymphohistiocytosis using both bone marrow and peripheral blood stem cells.
Br J Haematol.
96
1997
644
646
25
Jabado
N
de Graeff-Meeder
ER
Cavazzana-Calvo
M
et al
Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors.
Blood.
90
1997
4743
4748
26
Purtilo
DT
Cassel
CK
Yang
JP
et al
X-linked recessive progressive combined variable immunodeficiency (Duncan's disease)
Lancet.
1
1975
935
941
27
Coffey
AJ
Brooksbank
RA
Brandau
O
et al
Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene.
Nat Genet.
20
1998
129
135
28
Sayos
J
Wu
C
Morra
M
et al
The X-linked lymphoproliferative disease gene product SAP regulates signals induced through the co-receptor SLAM.
Nature.
395
1998
462
469
29
Seemayer
TA
Gross
TG
Egeler
RM
et al
X-linked lymphoproliferative disease: twenty-five years after the discovery.
Pediatr Res.
38
1995
471
478
30
Ventri
RW
Raich
PC
McClung
JE
Shah
SH
Sprinkle
PM
Lymphomatoid granulomatosis and Epstein-Barr virus.
Cancer.
50
1982
1513
1517
31
Guinee
D
Jr
Jaffe
E
Kingma
D
et al
Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis.
Am J Surg Pathol.
18
1994
753
764
32
Ilowite
NT
Fligner
CL
Ochs
HD
et al
Pulmonary angiitis with atypical lymphoreticular infiltrates in Wiskott-Aldrich syndrome: possible relationship of lymphomatoid granulomatosis and EBV infection.
Clin Immunol Immunopathol.
41
1986
479
484
33
Lipford
EH
Margolick
JB
Longo
DL
Fauci
AS
Jaffe
ES
Angiocentric immunoproliferative lesions: a clinicopathologic spectrum of post-thymic T-cell proliferations.
Blood.
72
1988
1674
1681
34
Wilson
WH
Kingma
DW
Raffeld
M
Wittes
RE
Jaffe
ES
Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-α 2b.
Blood.
87
1996
4531
4537
35
Kuehnle
I
Huls
MH
Liu
Z
et al
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation.
Blood.
95
2000
1502
1505
36
Welsh
RM
Jr
Zinkernagel
RM
Hallenbeck
LA
Cytotoxic cells induced during lymphocytic choriomeningitis virus infection of mice, II: “specificities” of the natural killer cells.
J Immunol.
122
1979
475
481
37
Benoit
L
Wang
X
Pabst
HF
Dutz
J
Tan
R
Cutting edge: defective NK cell activation in X-linked lymphoproliferative disease.
J Immunol.
165
2000
3549
3553
38
Parolini
S
Bottino
C
Falco
M
et al
X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells.
J Exp Med.
192
2000
337
346
39
Fleischer
G
Starr
S
Koven
N
Kamiya
H
Douglas
SD
Henle
W
A non-X-linked syndrome with susceptibility to severe Epstein-Barr virus infections.
J Pediatr.
100
1982
727
730
40
Yanagisawa
M
Kato
M
Ikeno
K
et al
Defective generation of killer cells against spontaneously Epstein-Barr virus (EBV)-transformed autologous B cells in a fatal EBV infection.
Clin Exp Immunol.
68
1987
251
258
41
Joncas
J
Monczak
Y
Ghihu
F
et al
Brief report: killer cell defect and persistent immunological abnormalities in two patients with chronic active Epstein-Barr virus infection.
J Med Virol.
28
1989
110
117
42
Okano
M
Matsumoto
S
Osato
T
Sakiyama
Y
Thiele
GM
Purtilo
DT
Severe chronic active Epstein-Barr virus infection syndrome.
Clin Microbiol Rev.
4
1991
129
135
43
Kawa-Ha
K
Franco
E
Doi
S
et al
Successful treatment of chronic Epstein-Barr virus infection with recombinant interleukin-2.
Lancet.
1
1987
154
44
Stephan
J
Donadieu
J
Le Deist
F
Blauche
S
Griscelli
C
Fischer
A
Treatment of familial hemophagocytic lymphohistiocytosis with anti-thymocyte globulins, steroids and cyclosporin A.
Blood.
82
1993
2319
2323
45
Walport
MJ
Davies
KA
Morley
BJ
Botto
M
Complement deficiency and autoimmunity.
Ann N Y Acad Sci.
815
1997
267
281
46
Truedsson
L
Fredrikson
GN
Sjoholm
AG
Complement deficiencies—an update.
Prog Immunodefic.
6
1996
97
104
47
Mullighan
CG
Marshall
SE
Welsh
KI
Mannose binding lectin polymorphisms are associated with early age of disease onset and autoimmunity in common variable immunodeficiency.
Scand J Immunol.
51
2000
111
122
48
Perniok
A
Wedekind
F
Herrmann
M
Specker
C
Schneider
M
High levels of circulating early apoptotic peripheral blood mononuclear cells in systemic lupus erythematosus.
Lupus.
7
1998
113
118
49
Mevorach
D
Zhou
JL
Song
X
Elkon
KB
Systemic exposure to irradiated apoptotic cells induce autoantibody production.
J Exp Med.
188
1998
387
392
50
Villa
A
Santagata
S
Bozzi
F
et al
Partial V(D)J recombination activity leads to Omenn's syndrome.
Cell.
93
1998
885
896
51
de Saint-Basile
G
Le Deist
F
de Villartay
JP
et al
Restricted heterogeneity of T lymphocytes in combined immunodeficiency with hypereosinophilia (Omenn's syndrome).
J Clin Invest.
87
1991
1352
1359
52
Omenn
GS
Familial reticuloendotheliosis with eosinophilia.
N Engl J Med.
273
1965
427
432
53
Villa
A
Sobacchi
C
Notarangelo
LD
et al
V(D)J recombination defects in lymphocytes: a severe immunodeficiency with a spectrum of clinical presentations due to RAG mutations.
Blood.
97
2001
81
88
54
Ahonen
P
Autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED): autosomal recessive inheritance.
Clin Genet.
27
1985
532
542
55
Nagamine
K
Peterson
P
Hamish
SS
et al
Positional cloning of the APECED gene.
Nat Genet.
17
1997
393
398
56
Bjorses
P
Halonen
M
Palvimo
JJ
et al
Mutations in the AIRE gene: effects on subcellular location and transactivation function of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protein.
Am J Hum Genet.
66
2000
378
392
57
Pitkanen
J
Doucas
V
Sternsdorf
T
et al
The autoimmune regulator protein has transcriptional transactivating properties and interacts with the common coactivator CREB-binding protein.
J Biol Chem.
275
2000
16802
16809
58
Zuklys
S
Bulciunaite
G
Agarwal
A
Fasler-Kan
E
Palmer
E
Hollander
GA
Normal thymic architecture and negative selection are associated with AIRE expression, the gene defective in the autoimmune-polyendocrinopathy-candidiasis-ectodermal dystrophy.
J Immunol.
165
2000
1976
1983
59
Pitkanen
J
Vahamurto
P
Krohn
K
Peterson
P
Subcellular localization of the autoimmune regulator protein. Characterization of nuclear targeting and transcriptional activation domain.
J Biol Chem.
276
2001
19597
19602
60
Lilic
D
Gravenor
I
Immunology of chronic mucocutaneous candidiasis.
J Clin Pathol.
54
2001
81
83
61
Canale
VC
Smith
CH
Chronic lymphadenopathy simulating malignant lymphoma.
J Pediatr.
70
1967
891
899
62
Rieux-Laucat
F
Blachere
S
Danielan
S
et al
Lymphoproliferative syndrome with autoimmunity: a possible genetic basis for dominant expression of the clinical manifestations.
Blood.
94
1999
2575
2582
63
Wang
J
Zheng
L
Lobito
A
et al
Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II.
Cell.
98
1999
47
58
64
Sneller
MC
Wang
J
Dale
JK
et al
Clinical, immunologic and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
Blood.
89
1997
1341
1348
65
Arkwright
PD
Rieux-Laucat
F
Le Deist
F
Stevens
RF
Angus
B
Cant
AJ
Cytomegalovirus infection in infants with autoimmune lymphoproliferative syndrome (ALPS).
Clin Exp Immunol.
121
2000
353
357
66
Straus
SE
Jaffe
ES
Puck
JM
et al
The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis.
Blood.
98
2001
194
200
67
Banchereau
J
Bazan
F
Blanchard
D
et al
The CD40 antigen and its ligand.
Ann Rev Immunol.
12
1994
881
922
68
Revy
P
Muto
T
Levy
Y
et al
Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2).
Cell.
102
2000
565
575
69
Allen
RC
Armitage
RJ
Conley
ME
et al
CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome.
Science.
259
1993
990
993
70
Wiley
JA
Harmsen
AG
CD40 ligand is required for resolution of Pneumocystis pneumonia in mice.
J Immunol.
155
1995
3525
3529
71
Levy
J
Espanol-Boren
T
Thomas
C
et al
Clinical spectrum of X-linked hyper-IgM syndrome.
J Pediatr.
131
1997
47
54
72
Notarangelo
LD
Hayward
AR
X-linked immunodeficiency with hyper-IgM (XHIM).
Clin Exp Immunol.
120
2000
399
405
73
Cosyns
M
Tsirkin
S
Jones
M
Flavell
R
Kikutani
H
Hayward
AR
Requirement of CD40-CD40 ligand interaction for elimination of Cryptosporidium parvum from mice.
Infect Immun.
66
1998
603
607
74
Lacroix-Desmazes
S
Resnick
I
Stahl
D
et al
Defective self-reactive antibody repertoire of serum IgM in patients with hyper-IgM syndrome.
J Immunol.
162
1999
5601
5608
75
Thomas
C
de Saint Basile
G
Le Deist
F
et al
Brief report: correction of X-linked hyper-IgM syndrome by allogeneic bone marrow transplantation.
N Engl J Med.
333
1995
426
429
76
Hadzic
N
Pagliuca
A
Rela
M
et al
Correction of the hyper-IgM syndrome after liver and bone marrow transplantation.
N Engl J Med.
342
2000
320
324
77
Khawaja
K
Gennery
AR
Flood
TJ
Abinun
M
Cant
AJ
Bone marrow transplantation for CD40 ligand deficiency: a single centre experience.
Arch Dis Child.
84
2001
508
511
78
Masternak
K
Barras
E
Zufferey
M
et al
A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients.
Nat Genet.
20
1998
273
277
79
Klein
C
Lisowska-Grospierre
B
LeDeist
F
Fischer
A
Griscelli
C
Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features and outcome.
J Pediatr.
123
1993
921
928
80
Elhasid
R
Etzioni
A
Major histocompatibility complex class II deficiency: a clinical review.
Blood Rev.
10
1996
242
248
81
Saleem
MA
Arkwright
PD
Davies
EG
Cant
AJ
Veys
PA
Clinical course of patients with major histocompatibility complex class II deficiency.
Arch Dis Child.
83
2000
356
359
82
Klein
C
Cavazzana-Calvo
M
LeDeist
F
et al
Bone marrow transplantation in major histocompatibility complex class II deficiency: a single-center study of 19 patients.
Blood.
85
1995
580
587
83
Griscelli
C
Lisowska-Grospierre
B
Mach
B
Combined immunodeficiency with defective expression in MHC class II genes.
Immunodefic Rev.
1
1989
135
153
84
Cotelingham
JD
Witebsky
FG
Hsu
SM
Blaese
RM
Jaffe
ES
Malignant lymphoma in patients with the Wiskott-Aldrich syndrome.
Cancer Invest.
3
1985
515
522
85
Sullivan
KE
Mullen
CA
Blaese
RM
Winkelstein
JA
A multiinstitutional survey of the Wiskott-Aldrich syndrome.
J Pediatr.
125
1994
876
885
86
Filipovich
AH
Krivit
W
Kersey
JH
Burke
BA
Fatal arteritis as a complication of Wiskott-Aldrich syndrome.
J Pediatr.
95
1979
742
744
87
Zhu
Q
Zhang
M
Blaese
RM
et al
The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene.
Blood.
86
1995
3797
3804
88
Villa
A
Notarangelo
L
Macchi
P
et al
X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene.
Nat Genet.
9
1995
414
417
89
Litzman
J
Jones
A
Hann
I
Chapel
H
Strobel
S
Morgan
G
Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome.
Arch Dis Child.
75
1996
436
439
90
Spickett
GP
Farrant
J
North
ME
Zhang
JG
Morgan
L
Webster
AD
Common variable immunodeficiency: how many diseases?
Immunol Today.
18
1997
325
328
91
Cunningham-Ruddles
C
Bodian
C
Common variable immunodeficiency: clinical and immunological features of 248 patients.
Clin Immunol.
92
1999
34
48
92
Uluhan
A
Sager
D
Jasin
HE
Juvenile rheumatoid arthritis and common variable hypogammaglobulinemia.
J Rheumatol.
25
1998
1205
1210
93
Washington
K
Stenzel
TT
Buckley
RH
Gottfried
MR
Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia.
Am J Surg Pathol.
20
1996
1240
1252
94
Hammarstrom
L
Vorechovsky
I
Webster
D
Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID).
Clin Exp Immunol.
120
2000
225
231
95
Kinlen
LJ
Webster
AD
Bird
AG
et al
Prospective study of cancer in patients with hypogammaglobulinaemia.
Lancet.
2
1985
263
266
96
Ariatti
C
Vivenza
D
Capello
D
et al
Common-variable immunodeficiency-related lymphoma associate with mutations and rearrangement of BCL-6: pathogenetic and histogenetic implications.
Hum Pathol.
31
2000
871
873
97
Hermaszewski
RA
Webster
AD
Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications.
Q J Med.
86
1993
31
42
98
Mullighan
CG
Fanning
GC
Chapel
HM
Welsh
KI
TNF and lymphotoxin-α polymorphisms associated with common variable immunodeficiency: role in the pathogenesis of granulomatous disease.
J Immunol.
159
1997
6236
6241
99
Fasano
MB
Sullivan
KE
Sarpong
SB
et al
Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of the literature.
Medicine (Baltimore).
75
1996
251
261
100
Sutor
G
Fabel
H
Sarcoidosis and common variable immunodeficiency. A case of a malignant course of sarcoidosis in conjunction with severe impairment of the cellular and humoral immune system.
Respiration.
67
2000
204
208
101
Mechanic
LJ
Dikman
S
Cunningham-Rundles
C
Granulomatous disease in common variable immunodeficiency.
Ann Intern Med.
127
1997
613
617
102
Wright
JJ
Wagner
DK
Blaise
RM
Hagengruber
C
Waldmann
TA
Fleisher
TA
Characterization of common variable immunodeficiency: identification of a subset of patients with distinctive immunophenotypic and clinical features.
Blood.
76
1990
2046
2051
103
Strober
W
Sneller
MC
IgA deficiency.
Ann Allergy.
66
1991
363
375
104
Liblau
RS
Bach
JF
Selective IgA deficiency and autoimmunity.
Int Arch Allergy Immunol.
99
1992
16
27
105
Cataldo
F
Marino
V
Ventura
A
Bottaro
G
Corazza
GR
Prevalence and clinical features of selective immunoglobulin A deficiency in coeliac disease: an Italian multicentre study. Italian Society of Paedatric Gastroenterology and Hepatology (SIGEP) and “Club del Tenue” Working Groups on Coeliac Disease.
Gut.
42
1998
362
365
106
Munks
R
Booth
JR
Sokol
RJ
A comprehensive IgA service provided by a blood transfusion center.
Immunohaematology.
14
1998
155
160
107
Pineda
AA
Taswell
HF
Transfusion reactions associated with anti-IgA antibodies: report of four cases and review of the literature.
Transfusion.
15
1975
10
15
108
Burks
AW
Sampson
HA
Buckley
RH
Anaphylactic reactions after γ-globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA.
N Engl J Med.
314
1986
560
564
109
Lilic
D
Sewell
WA
IgA deficiency: what we should—or should not—be doing.
J Clin Pathol.
54
2001
337
338
110
Heikkila
M
Koistinen
J
Lohman
M
Koskimies
S
Increased frequencies of HLA-A1 and -B8 in association with total lack, but not with deficiency of serum IgA.
Tissue Antigens.
23
1984
280
283
111
Levy
A
Michel
G
Lemerrer
M
Philip
N
Idiopathic thrombocytopenic purpura in two mothers of children with DiGeorge sequence: a new component manifestation of deletion 22q11.
Am J Med Genet.
69
1997
356
359
112
DePiero
AD
Lourie
EM
Berman
BW
Robin
NH
Zinn
AB
Hostoffer
RW
Recurrent immune cytopenias in two patients with DiGeorge/velocardiofacial syndrome.
J Pediatr.
131
1997
484
486
113
The International FMF Consortium
Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever.
Cell.
90
1997
797
807
114
Centola
M
Wood
G
Frucht
DM
et al
The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators.
Blood.
95
2000
3223
3231
115
Kastner
DL
Familial Mediterranean fever: the genetics of inflammation.
Hosp Pract (Off Ed).
33
1998
131
134
139-140, 143-146.
116
Ozen
S
New interest in an old disease: familial Mediterranean fever.
Clin Exp Rheumatol.
17
1999
745
749
117
Tekin
M
Yalcinkaya
F
Tumer
N
Akar
N
Misirhiogli
M
Cakar
N
Clinical, laboratory and molecular characteristics of children with familial Mediterranean fever-associated vasculitis.
Acta Paediatr.
89
2000
177
182
118
Galon
J
Aksentijevich
I
McDermott
MF
O'Shea
JJ
Kastner
DL
TNFRSF1A mutations and autoinflammatory syndromes.
Curr Opin Immunol.
12
2000
479
486
119
McDermott
MF
Aksentijevich
I
Galon
J
et al
Germline mutations in the extracellular domains of the 55kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.
Cell.
97
1999
133
144
120
Drenth
JP
Cuisset
L
Grateau
G
et al
Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper IgD Study Group.
Nat Genet.
22
1999
178
181
121
Kanegane
H
Tsukada
S
Iwata
T
et al
Detection of Bruton's tyrosine kinase mutations in hypogammaglobulinaemic males registered as common variable immunodeficiency (CVID) in the Japanese Immunodeficiency Registry.
Clin Exp Immunol.
120
2000
512
517
122
Plebani
A
Ugazio
AG
Meini
A
et al
Extensive deletion of immunoglobulin heavy chain constant region genes in the absence of recurrent infections: when is IgG subclass deficiency clinically relevant?
Clin Immunol Immunopathol.
68
1993
46
50
123
Farrington
M
Grosmaire
LS
Nonoyama
S
et al
CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency.
Proc Natl Acad Sci U S A.
91
1994
1099
1103
124
Sawabe
T
Horiuchi
T
Nakamura
M
et al
Defect of lck in a patient with common variable immunodeficiency.
Int J Mol Med.
7
2001
609
614
125
Morra
M
Silander
O
Calpe
S
et al
Alterations of the X-linked lymphoproliferative disease gene SH2D1A gene in common variable immunodeficiency syndrome.
Blood.
98
2001
1321
1325
126
Sanal
O
Ersoy
F
Yel
L
et al
Impaired IgG antibody production to pneumococcal polysaccharides in patients with ataxia-telangiectasia.
J Clin Immunol.
19
1999
326
334
127
Shovlin
CL
Simmonds
HA
Fairbanks
LD
et al
Adult onset immunodeficiency due to inherited adenosine deaminase deficiency.
J Immunol.
153
1994
2331
2339

Author notes

P. D. Arkwright, Academic Unit of Child Health, First Floor, St Mary's Hospital, Hathersage Road, Manchester, M13 0JH, United Kingdom; e-mail: peter_arkwright@lineone.net.

Sign in via your Institution